Literature DB >> 27368530

[HIV infection : Test and treatment].

J K Rockstroh1, J-C Wasmuth2.   

Abstract

In Europe depending on the country 15-80 % of all individuals infected with human immunodeficiency virus (HIV) are either not aware of the diagnosis or are diagnosed later. An early HIV diagnosis could, however, considerably improve the prognosis of individuals infected with HIV and decrease the risk of new infections; therefore, in the presence of indicator diseases, such as sexually transmitted diseases, oral thrush, herpes zoster and lymphoma, the performance of a HIV test is of utmost importance. A newly diagnosed HIV infection represents an indication for starting antiretroviral combination therapy independent of the clinical stage or CD4 cell count. A decline of the viral burden to below the limit of detection and subsequent continuous suppression of viral replication can prevent transition from HIV to acquired immune deficiency syndrome (AIDS) and if started early enough a normal life expectancy can be achieved. Challenges which remain in HIV therapy are the lifelong daily intake of medication and the complex long-term adverse effects.

Entities:  

Keywords:  Acquired immune deficiency syndrome; Antiretroviral agents; Candidiasis, oral; Helper cells; Late presenter

Mesh:

Substances:

Year:  2016        PMID: 27368530     DOI: 10.1007/s00108-016-0099-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA study 2001-2009.

Authors:  Mark Oette; Stefan Reuter; Rolf Kaiser; Thomas Lengauer; Gerd Fätkenheuer; Heribert Knechten; Martin Hower; Herbert Pfister; Dieter Häussinger
Journal:  Intervirology       Date:  2012-01-24       Impact factor: 1.763

2.  Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Authors:  Jürgen K Rockstroh; Edwin DeJesus; Jeffrey L Lennox; Yazdan Yazdanpanah; Michael S Saag; Hong Wan; Anthony J Rodgers; Monica L Walker; Michael Miller; Mark J DiNubile; Bach-Yen Nguyen; Hedy Teppler; Randi Leavitt; Peter Sklar
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

3.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Authors:  Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Lijie Zhong; Kitty Yale; Kirsten White; Brian P Kearney; Javier Szwarcberg; Erin Quirk; Andrew K Cheng
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

4.  Late presentation of HIV infection: a consensus definition.

Authors:  A Antinori; T Coenen; D Costagiola; N Dedes; M Ellefson; J Gatell; E Girardi; M Johnson; O Kirk; J Lundgren; A Mocroft; A D'Arminio Monforte; A Phillips; D Raben; J K Rockstroh; C Sabin; A Sönnerborg; F De Wolf
Journal:  HIV Med       Date:  2011-01       Impact factor: 3.180

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Authors:  Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

7.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

Authors:  J M Raboud; J S Montaner; B Conway; S Rae; P Reiss; S Vella; D Cooper; J Lange; M Harris; M A Wainberg; P Robinson; M Myers; D Hall
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

8.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Authors:  Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier
Journal:  Ann Intern Med       Date:  2014-10-07       Impact factor: 25.391

9.  Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Authors:  Ajay K Sethi; David D Celentano; Stephen J Gange; Richard D Moore; Joel E Gallant
Journal:  Clin Infect Dis       Date:  2003-09-19       Impact factor: 9.079

10.  Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).

Authors:  Ann K Sullivan; Dorthe Raben; Joanne Reekie; Michael Rayment; Amanda Mocroft; Stefan Esser; Agathe Leon; Josip Begovac; Kees Brinkman; Robert Zangerle; Anna Grzeszczuk; Anna Vassilenko; Vesna Hadziosmanovic; Maksym Krasnov; Anders Sönnerborg; Nathan Clumeck; José Gatell; Brian Gazzard; Antonella d'Arminio Monforte; Jürgen Rockstroh; Jens D Lundgren
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.